Baricitinib (Olumiant) is now available as an additional treatment option for patients admitted to hospital to manage the symptoms of COVID pneumonia.   A patient may therefore now be given an IL-6 inhibitor (tocilizumab or sarilumab) after treatment with baricitinib has been commenced (or vice versa), according to clinical judgement.  Baricitinib should not be routinely co-administered (i.e. given simultaneously) with an IL-6 inhibitor. However, in the situation of illness requiring critical care support or where a patient has deteriorated despite treatment, clinical judgement may deem co-administration appropriate. The summary clinical guide, covering all of the routinely available COVID treatment options for patients admitted to hospital due to COVID, has been updated to include this additional treatment option.   Clinicians are encouraged to continue to proactively support recruitment into trials developing further evidence in the treatment of COVID-19. Patients admitted to hospital due to COVID may be considered for entry into the RECOVERY or REMAP-CAP trials.